Pharmacogenetics and the practice of medicine

Nature

Volumn 405, Issue 6788, 2000, Pages 857-865

  Roses, Allen D ^a,b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS; DRUG DEVELOPMENT; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; DRUG THERAPY; GENE LINKAGE DISEQUILIBRIUM; GENE MAPPING; GENE MUTATION; GENETIC ANALYSIS; GENETIC DISORDER; HEALTH CARE DELIVERY; HUMAN; MEDICAL PRACTICE; MULTIFACTORIAL INHERITANCE; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

DELIVERY OF HEALTH CARE; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUG THERAPY; GENETIC SCREENING; GENOME; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 0034660560     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/35015728     Document Type: Review

References (59)

1. Curran, M. E. Potassium ion channels and human disease: phenotypes to drug targets? Curr. Opin. Biotechnol. 9, 565-572 (1998).
2. Marton, M. J. et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nature Med. 4, 1293-1301 (1998).
3. Wiley, S. R. Genomics in the real world. Curr. Pharmceut. Des. 4, 417-422 (1998).
4. Blackstock, W. P. & Weir, M. P. Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol. 17, 121-127 (1999).
5. Kozian, D. H. & Kirschbaum, B. J. Comparative gene-expression analysis. Trends Biotechnol. 17, 73-78 (1999).
6. Rockett, J. C., Esdaile, D. J. & Gibson, G. G. Differential gene expression in drug metabolism and toxicology: practicalities, problems and potential. Xenobiotica 29, 655-691 (1999).
7. Roses, A. D. Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J. Neuropathol. Exp. Neurol. 53, 429-437 (1994).
8. Saunders, A. M. Apolipoprotein E and Alzheimer's disease: an update on genetic and functional analyses J. Neuropathol. Exp. Neurol. (in the press).
9. Boschert, U., Merlo-Pich, E., Higgins, G., Roses, A. D. & Catsicas, S. Apolipoprotein E expression by neurons surviving excitotoxic stress. Neurobiol. Dis. 6, 508-514 (1999).
10. Xu, P. T. et al. Human apolipoprotein E2, E3 and E4 isoform-specific transgenic mice: human-like pattern of neuronal immunoreactivity in central nervous system not observed in wild type mice. Neurobiol. Dis. 3, 229-245 (1996).
11. Xu, P. T. et al. Regionally specific neuronal expression of human APOE gene in transgenic mice. Neurosci. Lett. 246, 65-68 (1998).
12. Xu, P. T. et al. Specific regional transcription of apolipoprotein E in human brain neurons. Am. J. Pathol. 154, 601-611 (1999).
13. Huang, J. T. et al. Interleukin-4-dependent production of PPAR-γ ligands in macrophage by 12/15-lipoxygenase. Nature 400, 378-382 (1999).
14. Kliewer, S. A. Lehmann, J. M. & Wilson, T. M. Orphan nuclear receptors: shifting endocrinology into reverse. Science 284, 757-760 (1999).
15. Barroso, I. et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402, 880-883 (1999).
16. Roses, A. D. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 47, 387-400 (1996).
17. Goate, A. et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706 (1991).
18. Levy-Lehad, E. et al. Candidate gene for the chromosome I familial Alzheimer's disease locus. Science 269, 973-977 (1995).
19. Sherrington, R. et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754-760 (1995).
20. Van Nostrand, W. E., Wagner, S. L., Haan, J., Bakker, E. & Roos, R. A. Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis-Dutch type share a decrease in cerebrospinal fluid levels of amyloid beta-protein precursor. Ann. Neurol. 32, 215-218 (1992).
21. Aitman, T. J. & Todd, J. A. Molecular genetics of diabetes mellitus. Baillieres Clin. Endocrinol. Metabol. 9, 631-656 (1995).
22. Sandford, A., Weir, T. & Pare, P. The genetics of asthma. Am. J. Respir. Crit. Care Med. 153, 1749-1765 (1996).
23. Schork, N. J, Genetics of complex disease: approaches, problems, and solutions. Am. J. Respir. Crit. Care Med. 156, S103-S109 (1997).
24. Concannon, P. et al. A second-generation screen of the human genome for susceptibility to insulin-dependent diabetes mellitus. Nature Genet. 19, 292-296 (1998).
25. Howard, T. D. et al. Genetics of allergy and bronchial hyperresponsiveness. Clin. Exp. Allergy 29(Suppl.), 86-89 (1999).
26. Talley, N. J. Irritable bowel syndrome: disease definition and symptom description. Eur. J. Surg. 583(Suppl.), 24-28 (1998).
27. Paterson, W. G. et al. Recommendations for the management of irritable bowel syndrome in family practice. IBS Consensus Conference Participants. Can. Med. Assoc. J. 161, 154-160 (1999).
28. Hamm, L. R. et al. Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria. Am. J. Gastroenterol. 94, 1279-1282 (1999).
29. Evans W. E. & Relling, M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
30. Meyer, U. A. & Zanger, U. M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37, 269-296 (1997).
31. Cohen, L. J. & DeVane, C. L. Clinical Implications of antidepressant pharmacokinetics and pharmacogenetics. Ann. Pharmacology 3, 1471-1476 (1998).
32. Rudorfer, M. V., Lane, E. A., Chang, W. H., Zhang, M. & Bower, W. Z. Dropamine pharmacokinetics in Chinese and Caucasian volunteers. Br. J. Clin Pharmacol. 17, 433-440 (1989).
33. Mueller, R. F. & Young, I. D. in Emery's Elements of Medical Genetics (ed. Kalow, W.) 169-175 (Churchill Livingstone, Edinburgh, 1997).
34. Zhao, L. P. Aragaki, C., Hsu, L. & Quizoit, F. Mapping of complex traits by single-nucleotide polymorphisms. Am. J. Hum. Genet. 63, 225-240 (1998).
35. Brookes, A. J. The essence of SNPs. Gene 234, 177-186 (1999).
36. Hacia, J. G. et al. Determination of ancestral allele for human single-nucleotide polymorphisms using high-density oligonucleotide arrays. Nature Genet. 27, 364-367 (1999).
37. Marez, D. et al. Polymorphism of the cytochrome P450 CYP2D8 gene is a European population: characterization of 48 mutations and 53 alleles, their fragnancies and evolution. Pharmacogenetics 7, 193-202 (1997).
38. McKusick, V. A. Foreword to Mendelian Inheritance in Men 10th edn, vol. 1, xv-xxxvii (The Johns Hopkins University Press, Baltimore, 1992).
39. Lai, E., Riley, J., Purvis, I. & Roses, A. 4-Mb high-density single nucleotide polymorphism-based map around human APOE. Genomics 54, 31-38 (1998).
40. Martin, E. R. et al. Analysis of association at single nucleotide polymorphisms in the APOE region. Genomics 63, 7-12 (2000).
41. Kruglyak, L. Prospects for whole-genome linkage dimorphism mapping of common diseas genes. Nature Genet. 22, 139-144 (1999).
42. Collins, A., Lonjou, C. & Morton, N. E. Genetic epidemiology of single-nucleotide polymorphisms. Proc. Natl Acad. Sci. USA, 96, 15173-15177 (1999).
43. Ott, J. Predicting the range of linkage disequilibrium. Proc. Natl Acad. Sci. USA. 97, 2-3 (2000).
44. Chen, J. et al. Microsphere-based assay for single-nucleotide polymorphism analysis using single base chain extension. Genome Res. 10, 549-557 (2000).
45. Roses, A. D., Manasco, P. & Freeman, A. J. Pharmacogenetics and genetics to discover new medicines. J. Comm. Biotech. (in the press).
46. Roses, A. D. Pharmacogenetics and the future of drug development and delivery. Lancet 355, 1358-1361 (2000).
47. Alon, U. et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc. Natl Acad. Sci. USA 96, 6745-6750 (1999).
48. Bonnie, A., Fijal, M. S., Hall, J. M. & Witte, J. S. Clinical trials in the genomic era. Effects of protective genotypes on sample size and duration of trial 2000. Gastroenterol. Clin. Trials 21, 7-20 (2000).
49. Lazarou, J., Pomeranz, B. H. & Corey, P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J. Am. Med. Assoc. 279, 1200-1205 (1998).
50. Wood, A. J., Stein, C. M. & Woosley, R. Making medicines safer - the need for an independent drug safety board. N. Engl. J. Med. 339, 1851-1854 (1998).
51. White, J. Targets and systems of health care coat control. J. Health Politics Policy Law 24, 653-696 (1999).
52. Mather, D. B., Sullivan, S. D., Augustein, D., Fullerton, P. & Atherton, D. Incorporating clinical outcomes and economic consequences into drug formulary decision: a practical approach. Am. J. Man. Care 5, 277-285 (1999).
53. McConnell, L. M. B. et al. Genetic testing and Alzheimer disease: recommendations of the Stanford Program in Genomics, Ethics, and Society. Genetic Testing 3, 3-12 (1999).
54. Koenig, B. A., Greely, H. T., McConnell, L. M., Silveberg, H. L. & Raffin, T. A. Genetic testing for BRCA1 and BRCA2: recommendations of the Stanford Program in Genomics, Ethics, and Society. Breast Cancer Working Group. J. Womens Health 7, 531-545 (1992).
55. Taningher, M., Malcarne, D., Izzotti, A., Ugolini, D. & Parodi, S. Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutation Res. 436, 227-261 (1999).
56. Saunders, A. M. et al. Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet 348, 90-93 (1996).
57. Mayeux, R., et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's disease Centers Consortium on Apolipoprotein E and Alzheimer's disease. N. Engl. J. Med. 338, 506-511 (1998). [Published erratum appears in N. Engl. J. Med. 338, 1325 (1998).]
58. Roses, A. D. Genetic testing for Alzheimer disease. Practical and ethical issues. Arch. Neurol. 54, 1226-1229 (1997).
59. Roses, A. D. Apolipoprotein E is a relevant susceptibility gene that affects the rate of expression of Alzheimer's disease. Neurobiol. Aging 15(Suppl 2), S165-S167 (1994).